LEI:
549300Q7EXQQH6KF7Z84
15 July
2024
RTW Biotech Opportunities
Ltd
Monthly Valuation Update and
Factsheet
+7.7% NAV movement for the
month
RTW Biotech Opportunities Ltd (the "Company") announces that the unaudited
net asset value attributable to the ordinary shares of the Company
at the close of business on 30 June 2024 (the "NAV") was US$655.4 million, or US$1.95
per ordinary share, +7.7% from the previous month.
The monthly factsheet
is available on the Company's website:
https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/
Highlights from the
Manager's quarterly letter:
· NAV per share returned +0.2% in the second quarter.
The Russell 2000 Biotech Index and the Nasdaq
Biotech Index returned -6.51% and +2.6% respectively in the second
quarter. Year to date, the Russell 2000 Biotech Index has returned
+1.68% and the Nasdaq Biotech Index has returned
+4.00%.
·
Avidity drove returns for
the second quarter in a row. The company shared Phase 1 data
for its second program, FSHD, another muscular dystrophy with no
approved drugs that ends with patients in wheelchairs. Treatment
improved muscle damage markers and increased muscle strength. After
some struggles the past couple years, second generation RNA
medicines are now delivering exciting breakthroughs.
· The Company completed investments in six new portfolio
companies in the first half of the year, including two in obesity.
This included the Manager's latest company creation, nicknamed
Hercules. Hercules is one of the largest biotech company creations
this year. Its clinical stage pipeline includes an injectable
GLP-GIP and an oral GLP in-licensed from Hengrui, one of China's
leading biopharma companies. The other was BioAge Labs. The Company
participated in BioAge's Series D financing round in which they
raise $170m to support Phase 2 clinical development of its lead
compound, Azelaprag, an oral drug with the potential to
significantly increase weight loss and improve body composition
(i.e. prevent muscle atrophy) when combined with any incretin (i.e.
GLP-1s and GIPs).
· Private holding, Numab Therapeutics, a next generation
immunology and immune-oncology company, announced that Johnson
& Johnson will acquire Yellow Jersey Therapeutics, its wholly
owned subsidiary, for $1.25bn.
For
Further Information
RTW
Investments, LP
|
+44
20 7959 6361
|
Woody Stileman, Managing Director,
Business Development
Krisha McCune, Director, Investor
Relations
|
biotechopportunities@rtwfunds.com
|
Buchanan (PR & Communications Adviser)
|
+44
20 7466 5107
|
Charles Ryland
|
|
Henry Wilson
|
|
George Beale
|
|
|
|
Deutsche Numis (Joint Corporate Broker)
|
+44
20 7260 1000
|
Freddie Barnfield
|
|
Nathan Brown
|
|
Euan Brown
|
|
|
|
BofA Securities (Joint Corporate Broker)
|
+44
20 7628 1000
|
Edward Peel
|
|
Alex Penney
|
|
Cadarn Capital (Distribution & IR
Partner)
|
+44
73 6888 3211
|
David Harris
|
|
Elysium Fund Management Limited
Joanna Duquemin Nicolle, Chief
Executive Officer
Sadie Morrison, Managing
Director
|
+44
14 8181 0100
|
Morgan Stanley Fund Services USA LLC
|
+1
914 225 8885
|
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW & RTWG) is an investment fund focused on identifying
transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a
long-term approach to support innovative businesses, RTW Biotech
Opportunities Ltd invests in companies developing next-generation
therapies and technologies that can significantly improve patients'
lives. RTW Biotech Opportunities Ltd is managed by RTW Investments,
LP, a leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.
***********
The information in this announcement
may include forward-looking statements, which are based on the
current expectations and projections about future events, and in
certain cases can be identified by the use of terms such as "may",
"will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives
thereon) or other variations thereon or comparable terminology.
These forward-looking statements, as well as those included in any
related materials, are subject to risks, uncertainties and
assumptions about the Company and/or its underlying investments,
including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use
of financing proceeds and future capital expenditures and
acquisitions. In light of these risks, uncertainties and
assumptions, the events in the forward-looking statements may not
occur.
The information contained in this
announcement is given at the date of its publication (unless
otherwise marked). No reliance may be placed for any purpose
whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or
fairness.
***********